BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14716830)

  • 1. Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.
    Zhuge J; Yu YN; Wu XD
    World J Gastroenterol; 2004 Jan; 10(2):234-7. PubMed ID: 14716830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line.
    Zhuge J; Luo Y; Yu YN
    World J Gastroenterol; 2003 Dec; 9(12):2732-6. PubMed ID: 14669323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.
    Zhu-Ge J; Yu YN; Qian YL; Li X
    World J Gastroenterol; 2002 Oct; 8(5):888-92. PubMed ID: 12378636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.
    Zhu GJ; Yu YN; Li X; Qian YL
    World J Gastroenterol; 2002 Apr; 8(2):318-22. PubMed ID: 11925616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue.
    Zhuge J; Yu YN
    World J Gastroenterol; 2004 Nov; 10(22):3356-60. PubMed ID: 15484318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells.
    Shiraishi T; Hosokawa M; Kobayashi K; Tainaka H; Yamaura Y; Taguchi M; Chiba K
    Drug Metab Dispos; 2002 Nov; 30(11):1201-5. PubMed ID: 12386125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
    Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
    J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
    Yu A; Dong H; Lang D; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Establishment of a HepG2 cell line stably expressing human cytochrome P450 1A2 and its metabolic activity].
    Zhu-Ge J; Ye S; Yu YN
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Oct; 32(5):403-6. PubMed ID: 14610739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells.
    Li X; Yu YN; Zhu GJ; Qian YL
    World J Gastroenterol; 2001 Dec; 7(6):841-5. PubMed ID: 11854913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
    Yu A; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level.
    Sarikaya D; Bilgen C; Kamataki T; Topcu Z
    Biopharm Drug Dispos; 2006 Nov; 27(8):353-9. PubMed ID: 16894644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
    Han SY; Zhao HY; Zhou N; Zhou F; Li PP
    J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dimethyl sulfoxide on the function of cytochrome P450 2D6 in HepG2 cells upon the co-expression with NADPH-cytochrome P450 reductase.
    Narimatsu S; Takatsu N; Yamano S; Inoue Y; Hanioka N; Kiryu K; Naito S; Gonzalez FJ; Yamamoto S
    Chem Biol Interact; 2006 Jan; 159(1):47-57. PubMed ID: 16214121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
    Yu A; Kneller BM; Rettie AE; Haining RL
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10.
    Rodrigues AD; Kukulka MJ; Roberts EM; Ouellet D; Rodgers TR
    Drug Metab Dispos; 1996 Jan; 24(1):126-36. PubMed ID: 8825200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.
    AlRabiah H; Ahad A; Mostafa GAE; Al-Jenoobi FI
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):707-713. PubMed ID: 29744741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, purification, and characterization of mouse CYP2d22.
    Yu AM; Haining RL
    Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate.
    McConnachie L; Bodor M; Kowdley K; Levy A; Tung B; Thummel K; Phillips B; Bajpai M; Chi V; Esmay JD; Shen DD; Ho RJ
    Clin Pharmacol Ther; 2004 Apr; 75(4):282-97. PubMed ID: 15060507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.